Bristol-Myers Squibb (NYSE:BMY) issued an update on its FY18 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of $3.15-3.30 for the period, compared to the Thomson Reuters consensus estimate of $3.23.
Shares of Bristol-Myers Squibb (BMY) opened at $60.96 on Tuesday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb has a 12 month low of $50.56 and a 12 month high of $66.10. The company has a market cap of $99,770.00, a P/E ratio of 24.00, a price-to-earnings-growth ratio of 2.19 and a beta of 1.08.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same period in the previous year, the business posted $0.63 EPS. equities research analysts predict that Bristol-Myers Squibb will post 2.99 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a dividend yield of 2.62%. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date was Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is 62.99%.
Several equities analysts have recently weighed in on BMY shares. Vetr raised shares of Bristol-Myers Squibb from a hold rating to a buy rating and set a $67.92 target price for the company in a report on Monday, October 9th. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a buy rating to a hold rating in a report on Thursday, November 2nd. BMO Capital Markets set a $49.00 target price on shares of Bristol-Myers Squibb and gave the company a sell rating in a report on Thursday, October 12th. Citigroup lifted their target price on shares of Bristol-Myers Squibb to $72.00 and gave the company a buy rating in a report on Wednesday, October 18th. Finally, Barclays lifted their target price on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the company an equal weight rating in a report on Friday, October 13th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Hold and an average target price of $65.38.
In related news, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Theodore R. Samuels II purchased 4,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average cost of $62.30 per share, with a total value of $249,200.00. Following the acquisition, the director now owns 22,000 shares in the company, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of BMY. UBS Asset Management Americas Inc. increased its holdings in Bristol-Myers Squibb by 10.0% in the 2nd quarter. UBS Asset Management Americas Inc. now owns 4,791,226 shares of the biopharmaceutical company’s stock worth $266,967,000 after acquiring an additional 434,072 shares in the last quarter. Van ECK Associates Corp increased its holdings in Bristol-Myers Squibb by 3.9% in the 2nd quarter. Van ECK Associates Corp now owns 785,824 shares of the biopharmaceutical company’s stock worth $43,786,000 after acquiring an additional 29,369 shares in the last quarter. Beaumont Financial Partners LLC increased its holdings in Bristol-Myers Squibb by 50.5% in the 2nd quarter. Beaumont Financial Partners LLC now owns 11,231 shares of the biopharmaceutical company’s stock worth $626,000 after acquiring an additional 3,769 shares in the last quarter. D.A. Davidson & CO. increased its holdings in Bristol-Myers Squibb by 0.6% in the 2nd quarter. D.A. Davidson & CO. now owns 189,479 shares of the biopharmaceutical company’s stock worth $10,557,000 after acquiring an additional 1,092 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Bristol-Myers Squibb by 3.9% in the 2nd quarter. Northern Trust Corp now owns 24,041,862 shares of the biopharmaceutical company’s stock worth $1,339,612,000 after acquiring an additional 910,496 shares in the last quarter. 69.70% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb (BMY) Releases FY18 Earnings Guidance” was first published by Stock Observer and is the sole property of of Stock Observer. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.thestockobserver.com/2018/02/06/bristol-myers-squibb-bmy-releases-fy18-earnings-guidance.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.